SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is trending following a second FDA Complete Response Letter for its EBVALLO cancer therapy, which now cites concerns over clinical trial design despite previously resolved manufacturing issues. The community is expressing significant frustration over the FDA's unexpected change in position and questioning the need for a new trial, especially given the drug's existing approval in Europe.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending lower amid a Bank of America downgrade citing over-optimistic forward estimates and heightened competitive concerns as Amazon Pharmacy now offers Novo Nordisk's popular weight-loss pill, which is notably absent from HIMS's platform. This is fueling a heated debate, with many viewing the dip as a long-term buying opportunity given HIMS's personalized healthcare and vertical integration strategy, while others anticipate further declines due to competitive pressures and regulatory scrutiny.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is highly discussed following new AI partnerships with Google, which integrate Gemini for enhanced shopping experiences and expand drone delivery services. The community is actively buzzing about this strategic pivot, viewing WMT increasingly as a tech-enabled retailer ahead of its anticipated Nasdaq-100 inclusion. This narrative emphasizes Walmart's innovation and evolving market position, sparking conversations about its "growth tech stock" valuation.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum driven by its announcement of a record total contract value exceeding a billion and a major new collaboration in genomic testing with Northwestern Medicine. The community is actively discussing the company's AI-driven growth, strategic partnerships, and Cathie Wood's recent share acquisitions, leading to speculation about further gains in the precision medicine sector.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent showcases of its advanced agentic and voice AI solutions at a major tech conference, drawing significant community discussion around new partnerships in automotive and robotics. Investors are also actively debating the company's unique technology, which emphasizes client data privacy, and its substantial short interest.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after announcing preliminary quarterly and full-year results that significantly beat revenue expectations, sparking strong bullish sentiment across the community. Investors are keenly discussing the impressive growth, coupled with high analyst price targets and the potential for a rally driven by the stock's low free float. However, some continue to voice concerns regarding the company's cash reserves and the ongoing risk of dilution.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is experiencing significant trending activity following a strong earnings report that propelled its share price upward, fueling speculation of a short squeeze. However, this momentum has met with strong opposing views and a sharp pullback, as recent indications of disappointing holiday sales and a tempered forward outlook trigger investor apprehension regarding its sustained valuation.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to a new partnership and pre-production order with a major U.S. defense contractor, signaling a potential larger military contract for AI-powered situational awareness in combat vehicles. The community is buzzing with anticipation for this significant defense deal, viewing OSS as an undervalued leader in the high-growth Edge AI and defense sectors with a remarkably low float and strong cash position after its recent strategic asset sale.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major focus as its upcoming earnings report highlights anticipated strong performance alongside warnings of substantial expense increases for the new year, which has recently spurred market volatility. Community discussions are actively weighing the bank's strategic moves into crypto trading and AI investments against a proposed credit card interest rate cap and its current valuation. The bank's financial health and outlook are closely watched as key indicators for the broader financial sector.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax (ABVX) is trending due to heightened speculation surrounding a potential takeover by Eli Lilly and other major pharmaceutical companies, with reports from French media and government sources fueling the buzz. The community is actively discussing an impending bidding war and significant premiums for its promising ulcerative colitis drug, obefazimod, which has demonstrated strong Phase 3 data. This innovative treatment positions Abivax as a highly attractive target in the competitive inflammatory bowel disease market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bull of the Day: Eli Lilly (LLY)

Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come. 

Incyte (NASDAQ:INCY) Price Target Raised to $94.00

Morgan Stanley raised their price target on shares of Incyte from $92.00 to $94.00 and gave the company an "equal weight" rating in a research report on Tuesday...

INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma

Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.

Robeco Institutional Asset Management B.V. Has $196.71 Million Stake in Incyte Corporation $INCY

Robeco Institutional Asset Management B.V. cut its position in Incyte Corporation (NASDAQ:INCY - Free Report) by 2.8% in the 3rd quarter, according to its most recent filing with the Securities and...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified...

CWA Asset Management Group LLC Acquires New Holdings in Incyte Corporation $INCY

CWA Asset Management Group LLC bought a new position in Incyte Corporation (NASDAQ:INCY - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional...

Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY

Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of Incyte Corporation (NASDAQ:INCY - Free Report) during the third quarter, according to the company in its most...

VIRGINIA RETIREMENT SYSTEMS ET Al Has $65.16 Million Holdings in Incyte Corporation $INCY

VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 4.5% in the 3rd quarter, according to its most recent 13F filing with the...

Incyte Corporation (NASDAQ:INCY) Receives Average Rating of "Hold" from Analysts

Shares of Incyte Corporation (NASDAQ:INCY - Get Free Report) have received a consensus rating of "Hold" from the twenty research firms that are covering the firm, MarketBeat Ratings reports. One...

22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co.

Burney Co. bought a new stake in Incyte Corporation (NASDAQ:INCY - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission...

Incyte Corp.

44th Annual J.P. Morgan Healthcare Conference

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$106.59
Prev Close	$106.87
Open	$106.76
Dividend Yield	0.00%
50-Day Moving Average	$101.54
Beta	0.52
Avg. Volume	2.09M
PE Ratio	17.93

52-Week High	$112.29
52-Week Low	$53.56
Market Capitalization	$20.79B
EPS (Annual)	$0.1549
Price to Book	4.51
Revenue Per Employee	$1.62M
Enterprise Value/EBITDA	N/A

INCY
Incyte Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INCY News

INCYIncyte Corp.